Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.
Pivot X, Cortés J, Lüftner D, Lyman GH, Curigliano G, Bondarenko IM, Ahn JH, Im SA, Litwiniuk M, Shparyk YV, Ho GF, Kislov NV, Wojtukiewicz M, Sarosiek T, Chae YS, Ahn JS, Jang H, Kim S, Lee J, Yoon Y. Pivot X, et al. Among authors: litwiniuk m. JAMA Netw Open. 2023 Apr 3;6(4):e235822. doi: 10.1001/jamanetworkopen.2023.5822. JAMA Netw Open. 2023. PMID: 37022687 Free PMC article. Clinical Trial.
Clinical practice in secondary prophylaxis and management of febrile neutropenia in Poland: results of the febrile neutropenia awareness project.
Wojtukiewicz M, Chmielowska E, Filipczyk-Cisarż E, Krzemieniecki K, Leśniewski-Kmak K, Litwiniuk MM, Wieruszewska-Kowalczyk K, Kosno-Kruszewska E. Wojtukiewicz M, et al. Among authors: litwiniuk mm. Contemp Oncol (Pozn). 2014;18(6):425-8. doi: 10.5114/wo.2014.47905. Epub 2014 Dec 31. Contemp Oncol (Pozn). 2014. PMID: 25784842 Free PMC article.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland.
Wojtukiewicz M, Chmielowska E, Filipczyk-Cisarż E, Krzemieniecki K, Leśniewski-Kmak K, Litwiniuk MM, Wieruszewska-Kowalczyk K, Kosno-Kruszewska E. Wojtukiewicz M, et al. Among authors: litwiniuk mm. Contemp Oncol (Pozn). 2014;18(6):419-24. doi: 10.5114/wo.2014.47904. Epub 2014 Dec 31. Contemp Oncol (Pozn). 2014. PMID: 25784841 Free PMC article.
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.
Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; LIBERATE Study Group. Kenemans P, et al. Lancet Oncol. 2009 Feb;10(2):135-46. doi: 10.1016/S1470-2045(08)70341-3. Epub 2009 Jan 23. Lancet Oncol. 2009. PMID: 19167925 Free article. Clinical Trial.
Breast cancer in young women.
Radecka B, Litwiniuk M. Radecka B, et al. Among authors: litwiniuk m. Ginekol Pol. 2016;87(9):659-663. doi: 10.5603/GP.2016.0062. Ginekol Pol. 2016. PMID: 27723074 Free article. Review.
Follow-up after breast cancer treatment.
Załuska-Kusz J, Litwiniuk M. Załuska-Kusz J, et al. Among authors: litwiniuk m. Rep Pract Oncol Radiother. 2022 Oct 31;27(5):875-880. doi: 10.5603/RPOR.a2022.0104. eCollection 2022. Rep Pract Oncol Radiother. 2022. PMID: 36523801 Free PMC article.
49 results